AIM ImmunoTech Inc. (AIM) Form 8-K — Sep 14, 2026
AIM ImmunoTech entered into two exchange agreements with lender Streeterville Capital between September 8 and 9, 2026, converting approximately $400,000 of its November 2025 promissory note into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. The underlying note, dated November 18, 2025, carried an original principal of $3,301,250, and the exchange shares are being issued under the Section 3(a)(9) exemption and delivered via DWAC free of restrictive legends. Stockholders pre-approved the conversion at the July 15, 2026 special meeting under NYSE American Company Guide Sections 713(a) and 713(b).
Key figures
- Debt Amount
- 400000
- Offering Price
- 0.228
- Shares Offered
- 1749434
- Original note date
- 2025-11-18
- Conversion price basis
- average conversion price, approximate
- Original note principal
- 3301250
- Stockholder approval date
- 2026-07-15
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.